- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04254913
Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With Gastrostomy
April 18, 2023 updated by: Mitsubishi Tanabe Pharma Corporation
To evaluate the pharmacokinetics of single doses of edaravone oral suspension in Amyotrophic Lateral Sclerosis Patients with gastrostomy
Study Overview
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chiba, Japan
- Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
The key criteria are listed below.
- Patients aged between 20 and 80 years at the time of informed consent
- Japanese patients
- Among patients with ALS, those "Clinically definite ALS," "Clinically probable ALS" or "Clinically probable-laboratory-supported ALS" according to El Escorial Revised Airlie House criteria
- ALS Patients with gastrostomy
- Patients who can consent to contraception
- Patients who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study
Exclusion Criteria:
The key criteria are listed below.
- Patients in whom the possibility could not be ruled out that the current symptoms were symptoms of a disease requiring differential diagnosis, such as cervical spondylosis and multifocal motor neuropathy
- Patients undergoing treatment for malignancy.
- Patients who have presence of clinically significant liver, heart, or renal disease requiring hospitalization (except ALS) and infections requiring antibiotics. Patients who have a problem in general condition and are judged ineligible by the Investigator
- Body mass index (BMI) of <15.0 or >30.0, or a body weight of <40 kg
- Patients judged by the investigator (or subinvestigator) to be unsuitable for the study for any other reason
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MT-1186
Patients receive the edaravone oral suspension.
|
Suspension
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Plasma Concentration Versus Time Curve From Time Zero up to the Last Quantifiable Concentration Time-point (AUC0-t) of Unchanged Edaravone
Time Frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
|
Maximum Plasma Concentration (Cmax) of Unchanged Edaravone
Time Frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
|
Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged Edaravone
Time Frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
|
Terminal Elimination Half-life (t1/2) of Unchanged Edaravone
Time Frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
|
Apparent Terminal Elimination Rate Constant (Kel) of Unchanged Edaravone
Time Frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
|
Mean Residence Time (MRT) of Unchanged Edaravone
Time Frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
|
Apparent Total Clearance (CL/F) of Unchanged Edaravone
Time Frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
|
Apparent Distribution Volume at Elimination Phase (Vz/F) of Unchanged Edaravone
Time Frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration.
|
|
Apparent Distribution Volume at Steady State (Vss/F) of Unchanged Edaravone
Time Frame: Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration
|
Plasma samples are collected: Day 1 at pre-dose, 0.25, 0.5, 1, 2, 4 and 8 hours; Day 2 at 24 hours after administration
|
|
Cumulative Amount of Drug Excreted in Urine (Ae) of Edaravone
Time Frame: Urine samples are collected: 0 to 8 hours after oral administration
|
This information will not be disclosed because it may identify the patient (N=1).
|
Urine samples are collected: 0 to 8 hours after oral administration
|
Cumulative Percentage of Drug Excreted in Urine (Ae) of Edaravone
Time Frame: Urine samples are collected: 0 to 8 hours after oral administration
|
This information will not be disclosed because it may identify the patient (N=1)
|
Urine samples are collected: 0 to 8 hours after oral administration
|
Renal Clearance (CLr) of Edaravone
Time Frame: Urine samples are collected: 0 to 8 hours after oral administration
|
This information will not be disclosed because it may identify the patient (N=1).
|
Urine samples are collected: 0 to 8 hours after oral administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With Adverse Events and Adverse Drug Reactions
Time Frame: The provision of informed consent to Day 8
|
The provision of informed consent to Day 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: General Manager, Mitsubishi Tanabe Pharma Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 24, 2020
Primary Completion (Actual)
April 16, 2020
Study Completion (Actual)
April 22, 2020
Study Registration Dates
First Submitted
January 23, 2020
First Submitted That Met QC Criteria
February 2, 2020
First Posted (Actual)
February 5, 2020
Study Record Updates
Last Update Posted (Actual)
January 24, 2024
Last Update Submitted That Met QC Criteria
April 18, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Spinal Cord Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Motor Neuron Disease
- Amyotrophic Lateral Sclerosis
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Neuroprotective Agents
- Protective Agents
- Antioxidants
- Free Radical Scavengers
- Edaravone
Other Study ID Numbers
- MT-1186-J05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Japanese Patients With ALS
-
Mitsubishi Tanabe Pharma CorporationCompletedJapanese Patients With ALSJapan
-
Meir Medical CenterUnknownPatients With Normal ECG | Patients With Pathological ECGIsrael
-
Centre Hospitalier Universitaire DijonCompletedPatients Undergoing Cardiac Surgery | Patients With Coronary Artery Bypass Surgery With CECFrance
-
Rennes University HospitalTerminated
-
Yonsei UniversityRecruitingPatients With DefibrillatorKorea, Republic of
-
Philogen S.p.A.TerminatedPatients With CancerItaly, United Kingdom
-
Centre Francois BaclesseRecruitingPatients With CancerFrance
-
Yonsei UniversityNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...Sir Run Run Shaw Hospital; Zhejiang Provincial People's HospitalActive, not recruitingCancer Patients With PICCChina
-
Bukwang PharmaceuticalCompletedPatients With LC-BKorea, Republic of
Clinical Trials on MT-1186
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Mitsubishi Tanabe Pharma CorporationCompletedHealthy Adult SubjectsJapan
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
Mitsubishi Tanabe Pharma America Inc.CompletedAmyotrophic Lateral Sclerosis (ALS)United States, Canada, Japan, France, Germany, Italy
-
Mitsubishi Tanabe Pharma CorporationCompletedJapanese Patients With ALSJapan
-
Mitsubishi Tanabe Pharma CorporationCompletedHealthy Adult SubjectsJapan
-
Mitsubishi Tanabe Pharma America Inc.TerminatedALSUnited States, Canada, Japan, Germany, Korea, Republic of, Switzerland
-
Mitsubishi Tanabe Pharma CorporationCompletedHealthy Adult SubjectsJapan
-
Mitsubishi Tanabe Pharma America Inc.CompletedALSUnited States, Canada, Japan, France, Germany, Italy
-
Mitsubishi Tanabe Pharma America Inc.TerminatedALSUnited States, Korea, Republic of, Canada, Germany, Japan, Italy, Switzerland